You are here: Industry Insights > Uterine Fibroids

News List

FDA Approves Myfembree as the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids drugs
May 27, 2021
MYOV and Pfizer today announced that the U.S. Food and Drug Administration (FDA) has approved Myfembree (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg), the first once-daily treatment for the management of heavy menstrual bleeding
EMA safety committee recommends withdrawal of ulipristal acetate marketing authorisation europeanpharmaceuticalreview
September 18, 2020
The EMA’s PRAC has recommended the revocation of the marketing authorisation for ulipristal acetate, after a review confirmed liver injury caused by the medicine.
Farrer Park Hospital Joins 44 Hospitals in Mainland China and Taiwan, China Region of China to Conduct HIFU Treatment for Uterine Fibroids on International Women's Day prnasia
March 06, 2020
Farrer Park Hospital announced today that it will be joining 44 high-intensity focal ultrasound (HIFU) centers in mainland China and Taiwan, China Region of China to perform HIFU treatment on women with uterine fibroids.
AbbVie's Orilissa makes its uterine fibroids case with double phase 3 win fiercepharma
November 16, 2018
AbbVie’s Orilissa (elagolix) snagged its first FDA approval over the summer, and now it’s looking to make it two.
AbbVie, Neurocrine’s fibroid drug hits PhIII targets pharmatimes
July 24, 2018
A second late-stage study assessing AbbVie and Neurocrine’s experimental drug elagolix in women with uterine fibroids has met its primary endpoint.
Allergan, Gedeon’s fibroid drug hits PhIII targets pharmatimes
January 19, 2017
Allergan and Gedeon Richter are gearing up to file ulipristal acetate in the US in the second half of this year, in the hope of securing approval for the first oral treatment option for women suffering from uterine fibroids in the country.
Allergan and Gedeon Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg i americanpharmaceuticalreview
January 18, 2017
Allergan and Gedeon Richter have announced positive results from Venus II, the second of two pivotal phase III clinical trials evaluating the efficacy and safety of ulipristal acetate in women with abnormal bleeding due to uterine fibroids.